12-month Retention Research Articles

Using positive deviance to enhance HIV care retention in South Africa: development of a compassion-focused program to improve the staff and patient experience

BackgroundHIV burden remains high in South Africa despite intensive efforts to curtail the epidemic. Public primary care facilities, where most people with HIV (PWH) in South Africa receive treatment, face myriad challenges retaining patients on antiretroviral therapy (ART). Nevertheless, some facilities manage to consistently retain PWH in care. We used a participatory positive deviance (PD) approach to discover characteristics of primary care facilities with above-average 12-month retention rates to develop an intervention.MethodsWe conducted 11 in-depth leadership interviews, 9 staff focus groups with 29 participants, 11 patient focus groups with 45 participants, 23 patient shadowing visits, and multiple facility observations in each of 3 high- and 3 low-retention public primary care facilities in Cape Town, South Africa. Using PD, an asset-based approach to behavior change that consists of discovering how high-performing outliers succeed despite sizable barriers, and then using those data to develop interventions for low performers, we analyzed data to discover dominant characteristics of higher-retention facilities that might be contributing to higher retention rates.ResultsDominant themes found in higher-retention facilities were compassionate, respectful, and patient-centered care; higher staff morale, passion for the work, and team cohesion; efficient workflow procedures; and a welcoming physical environment. From these themes, we developed the multidimensional Connect intervention, consisting of strategies within three domains: (1) engage, encourage, and support staff (e.g., a monthly staff support huddle, a compassion training); (2) expedite and augment workflow procedures (e.g., adjust folder system to lower wait times); and (3) create a welcoming physical environment (e.g., fresh paint and plants in the waiting area).ConclusionsA PD approach enabled us to identify factors that could be contributing to higher ART retention rates within low-resource public sector primary care facilities in Cape Town, South Africa, and to develop a multidimensional intervention. If effective after a future trial, the intervention could be a feasible, affordable complement to existing programs aimed at improving care for PWH.

Predicting abatacept retention using machine learning

BackgroundThe incorporation of machine learning is becoming more prevalent in the clinical setting. By predicting clinical outcomes, machine learning can provide clinicians with a valuable tool for refining precision medicine approaches and improving treatment outcomes.MethodsThis was a post hoc analysis of pooled patient-level data from the global, real-world ACTION and ASCORE trials in patients with rheumatoid arthritis (RA) initiating abatacept. Patient demographic and disease characteristics were input across 10 machine learning models used to predict 12-month treatment retention. Retention was defined as treatment for > 365 days or ≤ 365 days in patients who achieved remission or major clinical response (based on European Alliance of Associations for Rheumatology response criteria). The pooled dataset was split into a training/validation cohort for model development and a test cohort for an unbiased evaluation of performance. SHapley Additive exPlanation (SHAP) values determined the level of importance and directionality for key patient features predicting abatacept retention.ResultsThe pooled ACTION and ASCORE dataset included 5320 patients with RA (mean [standard deviation] age 57.7 [12.7] years; 79% female). The 12-month abatacept retention rate was 61% (n = 3236) with a discontinuation rate of 39% (n = 2037). In the training set (n = 4218), the gradient-boosting classifier model demonstrated the best performance (testing accuracy: 62%). This model had an area under the receiver operating characteristic curve (95% confidence interval) of 0.620 (0.586, 0.653) and F1 score of 0.659 (0.625, 0.689) in the test set of patients (n = 1055). Using this model, the five most important variables predicting 12-month abatacept retention were low body mass index (BMI), low American College of Rheumatology functional status class, anti-citrullinated protein antibody (ACPA) positivity, low Patient Global Assessment, and younger age.ConclusionsThe gradient-boosting classifier model identified key patient features predictive of abatacept retention from this large, real-world study population. The SHAP values conveyed the directionality and importance of BMI, functional status, ACPA serostatus, Patient Global Assessment, and age for abatacept retention. Findings are consistent with previous observations and help validate the machine learning approach for predictive modelling in RA treatment, and may help inform clinical decision making.Trial registrationNCT02109666 (ACTION), NCT02090556 (ASCORE).

Efficacy, safety, and tolerability of adjunctive perampanel in the treatment of pediatric patients aged 4–18 years with epilepsy: A single-center, retrospective, observational real-world study

PurposeTo observe the efficacy, safety, and tolerability of perampanel (PER) as add-on therapy in children aged 4–18 years with epilepsy in a real-world environment. MethodsA single-center, retrospective, observational study was conducted at the First Affiliated Hospital of Fujian Medical University enrolling children with epilepsy aged 4–18 years who received PER as add-on therapy from January 2021 to November 2022 with 12 months of follow-up. Outcomes included 3-, 6- and 12-month retention, seizure freedom, responder rates, and adverse events (AEs) throughout follow-up. ResultsSeventy-eight children were included, of whom three were lost to follow-up. The responder rate at follow-up of 12 months was 54.7 %, the seizure-free rate was 32.0 % and the retention rate was 81.3 %. The number of seizures at baseline was a factor influencing the efficacy of the PER. Nine children reported AEs, with dizziness, drowsiness, and irritability being common. ConclusionsPER is safe, effective, and well tolerated for the treatment of children aged 4–18 years with epilepsy in clinical practice and is a potential option for refractory epilepsy. Patients with lower baseline seizure frequencies are more likely to exhibit a favorable response to PER.

Black Children's Perceptions of Parental Support and Parenting Practices: 6-Month Weight Loss and Retention in a Pediatric Weight Management Program.

Black families are less likely to continue in pediatric weight management programs (PWMPs) and have less optimal outcomes. Few studies have examined how parenting practices and perceived support influence Black children's retention and weight loss in PWMPs. To fill this gap, this study sampled Black children and their parent (N=49) who were participating in a Midwest PWMP to explore how children's reports of parental support and parenting practices at program initiation associate with early weight loss 3- and 6-month and retention at 6-month in the PWMP. There were no significant findings for the association of children's reports of parenting practices and their perceptions of parents' support for making health changes in the PWMP. However, the findings were in the anticipated direction, with effect sizes ranging from -0.92 to 0.42. Children who reported that their parent was supportive of their behavior change had less weight loss (i.e., increases in BMIz) from baseline to 3months than those who perceived their parent's as unsupportive or neither supportive or unsupportive (p=0.004). There were no significant correlations between BMIz change at 3 or 6months and reports of parenting practices. Additional research and with a larger sample are needed to further understand how parenting practices and support are associated with healthy behavior changes and retention of Black children and families in PWMPs.

Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease.

To evaluate the efficacy and safety of first-line targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in patients with rheumatoid arthritis (RA) and chronic kidney disease (CKD). This retrospective cohort study included 216 patients with RA prescribed their first tsDMARDs at two hospitals between 2013 and 2022. Dose reduction and contraindication guidelines for tsDMARDs according to kidney function were followed. The patients were categorised by kidney function and tsDMARD modality. The primary outcome was the 24-month drug retention rate, and the secondary outcomes were changes in the Disease Activity Score 28-C-reactive protein (DAS28-CRP) level, prednisolone dosage, and reasons for discontinuation. The 24-month drug retention rates according to the estimated glomerular filtration rate (eGFR) (≥60, 30-60, or < 30 mL/min/1.73 m2) were as follows: all tsDMARDs (46.0, 44.1, 47.1%), tofacitinib (55.9, 53.3, 66.7%), baricitinib (64.2, 42.0%), and peficitinib (36.4, 44.1, 40.0%). Even in groups with lower kidney function, the drug retention rate was maintained (adjusted hazard ratio was 1.14 (95% confidence interval, 0.81-1.62), p= 0.45). Patients had a decreased DAS28-CRP (p< 0.01) and a reduced prednisolone dosage (p< 0.01) over the six-month period following tsDMARD initiation. The incidence of herpes zoster and deep vein thrombosis (DVT) was higher in the group with an eGFR <30 mL/min/1.73 m2, but not statistically significant. tsDMARDs have demonstrated efficacy and safety in patients with RA and CKD; however, clinicians should consider the potential for herpes zoster and DVT in patients with eGFR <30 mL/min/1.73 m2.

Lessons Learned in Virtual Launch of an Antenatal Opioid Exposure Study During the COVID-19 Pandemic.

The COVID-19 pandemic prompted researchers to develop new ways to design and launch studies and recruit and retain participants. Pregnant women and infants are considered vulnerable populations in research, and families affected by substance use are particularly difficult to recruit and retain. Recruitment for studies involving medical technologies such as MRI can also be difficult due to misconceptions and fear of the technologies. To describe "lessons learned" during the launch of the Outcomes of Babies with Opioid Exposure (OBOE) study, including successes and challenges when working with high-risk infants and families and the importance of engaging participants through recruitment materials and retention efforts. The OBOE study is a multisite prospective longitudinal cohort study comparing infants with antenatal opioid exposure to unexposed controls from birth to 2 years of age. Chi-square tests were used to examine refusal reasons among caregivers of eligible infants by exposure group and differences in 6-month retention among subgroups based on social determinants of health. Four factors were essential in establishing the Consortium, implementing the study, and retaining participants: (a) creating venues for collaboration, (b) pivoting from in-person to virtual training, (c) anticipating potential enrollment barriers and addressing them directly, and (d) engaging participants through recruitment materials and retention efforts. With these factors in place, only 5% of caregivers of eligible opioid-exposed infants and 8% of control infants declined to participate in the study because of MRIs. Of 310 enrolled infants, 234 infants had attended the 6-month visit. Subgroups of enrolled infants were similar in retention at 6 months. Reporting our successes and challenges in setting up a nationwide consortium during the pandemic may help other consortia that need to be set up virtually. We anticipated that the serial MRIs would be a barrier to participation; however, few indicated they refused to participate because of MRIs, suggesting our efforts to address this potential barrier to enrollment were successful.

Looking under the hood of a hybrid two-way texting intervention to improve early retention on antiretroviral therapy in Malawi: an implementation fidelity evaluation

BackgroundWhile key to interpreting findings and assessing generalizability, implementation fidelity is underreported in mobile health (mHealth) literature. We evaluated implementation fidelity of an opt-in, hybrid, two-way texting (2wT) intervention previously demonstrated to improve 12-month retention on antiretroviral therapy (ART) among people living with HIV (PLHIV) in a quasi-experimental study in Lilongwe, Malawi.MethodsShort message service (SMS) data and ART refill visit records were used to evaluate adherence to 2wT content, frequency and duration through the lens of the Conceptual Framework for Implementation Fidelity. Message delivery and 2wT participant interactions were considered across four core 2wT components: 1) weekly motivational SMS messages; 2) proactive SMS appointment reminders; 3) SMS reminders after missed appointments; and 4) interactive messaging with 2wT staff about transfers and appointment rescheduling. Using mixed-effects logistic regression models adjusted for participant demographics, we examined the effect of core 2wT component fidelity on a) on-time appointment attendance and b) timely return to care after a missed appointment, presenting adjusted odds ratios (aORs) and 95% confidence intervals (CIs).ResultsThe 468 2wT participants had a median of 52 study weeks (interquartile range [IQR] 34 – 52) with 6 ART appointments (IQR 4—7) of which 2 (IQR 1 – 3) were missed. On average, participants received a motivation message for 75% (IQR 56%—83%) of enrolled weeks, a reminder before 83% (IQR 67%—100%) of appointments, and after 67% (IQR 0%—100%) of missed appointments. Participants reported 9 transfers and rescheduled 46 appointments through 2wT prompts; 196 appointments were changed via unprompted interaction. Participants with 10% higher expected motivation message delivery were more likely to attend clinic appointments on time (aOR: 1.08; 95%CI: 1.01 – 1.16, p = 0.03). Receiving and responding to an appointment reminder in any way were also associated with increased on-time appointment attendance (aOR: 1.35; 95%CI: 1.03 – 1.79, p = 0.03 and aOR: 1.47, 95%CI: 1.16 – 1.87, p = 0.001, respectively). No associations were found for 2wT messages and timely return to care following a missed appointment.ConclusionGreater 2wT implementation fidelity was associated with improved care outcomes. Although implementation fidelity monitoring of mHealth interventions is complex, it should be integrated into study design.

What About Nights, Weekends, and Wait Times? Adding an On-Demand Facilitated Telemedicine Buprenorphine Component to a Community-Based Peer Support Outreach Program.

In 2020, loosened federal regulations allowed for buprenorphine for opioid use disorder to be initiated via telemedicine. In response to these regulatory changes and growing racial inequities in overdose in St. Louis, MO, a local, peer-led outreach program incorporated a new rapid access (RA) to buprenorphine program. RA facilitated same-day buprenorphine access by conducting peer-facilitated telemedicine visits in community settings. This study used logistic regression to compare 1- and 3-month treatment and buprenorphine retention between clients in the RA and Traditional (ie, linkage to brick-and-mortar prescribers within 1-3 days) programmatic arms of a peer-led outreach program between December 2020 and June 2022. Propensity score matching allowed participants across groups to be matched on key factors (eg, sex, race, homelessness). Racial differences in program receipt/enrollment were also assessed through Chi-squared tests. Total program participation (N = 4139) included 1% (n = 52) in the RA program. Those in RA were more likely to be in treatment at 1 and 3 months and more likely to be on buprenorphine at 3 months compared to those in the Traditional group. The RA program included more White and fewer Black clients than expected. Four of the 8 reasons for non-enrollment differed by race, with Black individuals more likely to already have treatment secured but also more likely to decline the program or be unable to be contacted. This study is the first to demonstrate sustained benefits in treatment and medication engagement following same-day access to buprenorphine via community-based, peer-facilitated telemedicine. Lower-than-expected enrollment of Black individuals indicates a need for more culturally responsive implementation strategies for peer- and telemedicine-facilitated programs.

Looking under the hood of a hybrid two-way texting intervention to improve early retention on antiretroviral therapy in Malawi: an implementation fidelity evaluation.

While key to interpreting findings and assessing generalizability, implementation fidelity is underreported in mobile health (mHealth) literature. We evaluated implementation fidelity of an opt-in, hybrid, two-way texting (2wT) intervention previously demonstrated to improve 12-month retention on antiretroviral therapy (ART) among people living with HIV (PLHIV) in a quasi-experimental study in Lilongwe, Malawi. Short message service (SMS) data and ART refill visit records were used to evaluate adherence to 2wT content, frequency and duration through the lens of the Conceptual Framework for Implementation Fidelity. Message delivery and 2wT participant interactions were considered across four core 2wT components: 1) weekly motivational SMS messages; 2) proactive SMS appointment reminders; 3) SMS reminders after missed appointments; and 4) interactive messaging with 2wT staff about transfers and appointment rescheduling. In mixed-effects logistic regression, associations were assessed between 2wT messages and on-time appointment attendance and timely return to care after a missed appointment, respectively, presenting odds ratios (ORs) and 95% confidence intervals (CIs). The 468 2wT participants had a median of 52 study weeks (interquartile range [IQR] 34-52) with 6 ART appointments (IQR 4-7) of which 2 (IQR 1-3) were missed. On average, participants received a motivation message for 75% (IQR 56% - 83%) of enrolled weeks, a reminder before 83% (IQR 67% - 100%) of appointments, and after 67% (IQR 0% - 100%) of missed appointments. Participants reported 9 transfers and rescheduled 46 appointments through 2wT prompts; 196 appointments were changed via unprompted interaction. Participants with 10% higher expected motivation message delivery were more likely to attend clinic on time (OR: 1.13; 95%CI: 1.06-1.20, p < 0.001) and return to care within 14 days of a missed appointment (OR: 1.12; 95%CI: 1.03-1.22, p = 0.01). Receiving an appointment reminder increased on-time attendance (OR: 1.83; 95%CI: 1.44-2.33, p < 0.001). Greater 2wT implementation fidelity was associated with improved care outcomes. Although implementation fidelity monitoring of mHealth interventions is complex, it should be integrated into study design.

Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and Discontinuation.

Some concerns remain about the safety of nintedanib in patients with rheumatoid arthritis-related interstitial lung disease (RA-ILD), such as in the presence of comorbidities or in combination with biologic, targeted synthetic, and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). In this multicenter study, we retrospectively evaluated the safety of nintedanib in a real-world population of patients with RA-ILD from the Italian Group for the Study of Early Arthritis (GISEA) registry and the possible role of comorbidities and DMARDs on drug safety and withdrawal. Our secondary aim was to investigate the causes of nintedanib discontinuation. Sixty-five patients treated with nintedanib in accordance with the current therapeutic indications were enrolled in the study. Nintedanib was prescribed in combination with DMARDs and/or steroids in 62 patients (95.4%). The 12-month retention rate of nintedanib was 76.7% and the drug was effective in about 80% of patients with ≥ 6 months of follow-up. Adverse events (AEs) were recorded in 36 subjects (55.3%), and these were mainly gastroenteric. Thirty-one subjects required a reduction of the nintedanib dose; among them, a transient or permanent reduction of the daily dose of nintedanib allowed the continuation of the treatment in 22, whereas 15 (23.1%) withdrew from the drug. All reductions and discontinuations were owing to treatment-related AEs. Comorbidities were significantly associated with side effects in multivariate analysis, whereas AEs due to nintedanib were the main cause of discontinuation. Combination therapy with DMARDs did not reduce the safety and effectiveness of nintedanib, and AEs were the main cause of drug withdrawal or dose reduction, mainly owing to comorbidities.

Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study.

To assess short-term barnidipine efficacy and tolerability on Systemic Sclerosis (SSc)-Raynaud's phenomenon (RP). We retrospectively evaluated patients with SSc starting barnidipine 10mg/day. Raynaud's Condition Score (RCS) and mean blood pressure (MBP) were assessed at baseline and 6-month follow-up. Discontinuation rates and adverse events (AEs) were compared with retrospectively evaluated patients who started MR-nifedipine 20mg/day at our centre. Sixty-four patients (29 barnidipine, 35 MR-nifedipine) were evaluated. Most patients starting barnidipine had a previous CCB exposure (69%; 57.9% of these were withdrawn for AEs). During follow-up, RCS decreased significantly (6.6 ± 1.8 vs 4.4 ± 1.8, p < 0.001), while the MBP did not change significantly (86.4 ± 8.4 vs 85 ± 7.3mmHg; p = 0.36). Nine patients (31%) discontinued barnidipine during the follow-up (AEs 6/9, inefficacy 3/9). Previous CCB failure did not predict barnidipine withdrawal (OR = 0.188 95%CI [0.02-1.8]; p = 0.147). No predictors of barnidipine withdrawal were found, and no clinical or demographic differences were found between patients withdrawing and continuing barnidipine. The 6-month retention rates of barnidipine and MR-nifedipine did not differ significantly (69 vs 80%; log-rank p = 0.23), and the two groups had a similar incidence of AEs leading to discontinuation (20.1 vs 17%; p = 0.48). Barnidipine could be an effective and well-tolerated therapeutic option to treat SSc-RP, even in patients previously failing other CCBs. Key Points •Calcium channel blockers (CCBs) currently represent the first-line treatment forRaynaud's phenomenon secondary to Systemic Sclerosis (SSc-RP). However, littledata exists about using novel CCBs, such as barnidipine, in this condition. •This study retrospectively evaluated patients with SSc-RP treated with barnidipine toassess its short-term efficacy. To serve as a control group for tolerability, weretrospectively compared these patients with others starting modified release-nifedipine (MR-nifedipine). •In patients treated with barnidipine, we observed a significant decrease in Raynaud's condition score at the 6-month follow-up without substantial changes in mean blood pressure. •The proportion of adverse events and drug withdrawal rate between patients starting barnidipine and MR-nifedipine did not differ significantly, even in patients starting barnidipine after previously failing other CCBs.

Investigation of changes caused by Rapid Maxillary Expansion in mandibular bone and temporomandibular joint trabecular structure using fractal analysis

BackgroundThe aim of this study is to evaluate the changes in the trabecular structure of the mandibular bone and temporomandibular joint following Rapid Maxillary Expansion.MethodsThirty-nine patients who received Rapid Maxillary Expansion treatment in the Department of Orthodontics of the Faculty of Dentistry were selected from the archieve for the study. Trabecular structure changes of the angulus mandible, corpus mandible, and condyle regions were examined using fractal analysis on the dental panoramic radiographs. Radiographs taken before the treatment (T0) and at the end of the 3-month retention period (T1) of the patients.ResultsThere was no statistically significant difference between T0 and T1 in the condyle, ramus mandible, and corpus mandible regions depending on time and sex. (p < 0.05)ConclusionThe results of this study showed that Rapid Maxillary Expansion treatment does not have a significant impact on the trabecular structure of the mandible and temporomandibular joint depending on time and gender.

Poly-ether-ether-ketone (PEEK) versus dead-soft coaxial bonded retainers: a randomized clinical trial. Part 1. Stability, retainer failure, and participant satisfaction.

Poly-ether-ether-ketone (PEEK) was introduced in dentistry as an alternative to metal alloys. To assess the effectiveness of PEEK-fixed retainers in preserving the stability of mandibular anterior and participant satisfaction as compared to the Dead-soft coaxial fixed retainer (DSC). A single-centre, two-arm parallel groups randomized clinical trial. The patients treated with pre-adjusted orthodontic appliances who have a Little's Irregularity Index (LII) ≤ 0.5mm have been enrolled in the trial. PEEK retainers were prepared to round 0.8mm wire by computer-aided design and manufacturing, and the DSC wire was carefully adapted to the lingual surface of the lower anterior teeth. The primary outcome was the stability of lower anterior teeth as assessed by LII, while the secondary outcomes were changes in occlusal parameters, retainer failure, and patient satisfaction. The data were collected at the debonding stage (T0), 1 month (T1), 3 months (T3), and 6 months (T6) after starting the trial, except for patient's satisfaction, which was recorded using an electronic form at T1 and T6. Single blinding of participants. A total of 46 participants with an age range of 12-28 years old were randomly allocated to the two groups (n = 23 in each). Only one participant dropped out; therefore, 45 participants were analysed. The DSC group showed a significant increase in LII at T3. Both retainer groups had comparable occlusal measurements, failure frequency, and survival time, with no significant difference. The patients in the DSC group reported a statistically significant perception of change in the position of their teeth compared to those in the PEEK group. No harmful effects have been reported. Limited follow-up duration and the inability to blind the operator due to the nature of the intervention. After 6-month retention, the PEEK retainer was equally effective to DSC retainers in maintaining the teeth alignment, with no significant differences regarding the failure frequency, survival rate, and general patient satisfaction. https://register.clinicaltrials.gov. (NCT05557136).

Understanding health literacy's moderating role in remote monitoring for adjuvant endocrine therapy: Findings from a randomized clinical trial.

45 Background: Despite the efficacy of oral adjuvant endocrine therapy (AET) for improving survival among women with hormone receptor-positive early-stage breast cancer, adherence rates remain low. Our THRIVE study (NCT03592771) investigated the effectiveness of a mobile health remote monitoring app with and without tailored educational messages on AET adherence among women with breast cancer and found no statistically significant treatment effects on 1-year AET adherence overall. Health literacy contributes to patients’ understanding of their treatment plans. We conducted a post hoc analysis of the THRIVE study to examine if health literacy moderates the effectiveness of this intervention. Methods: This non-blinded randomized controlled trial included women with early-stage breast cancer prescribed AET at a large cancer center with 14 clinics across three states. Participants used a pillbox to electronically monitor AET adherence for 1 year and completed surveys at enrollment. Consented participants were randomized into (1) “App”, receiving access to the study adherence and symptom monitoring app for 6 months, with increasing/severe symptoms and missed doses reported in the app triggering follow-ups from the oncology team; (2) “App+Feedback”, receiving additional weekly text messages about managing symptoms, adherence, and communication for 6 months; or (3) “Enhanced Usual Care (EUC).” The primary outcome was 1-year AET adherence captured with the pillbox (≥80% Proportion of Days Covered [PDC] vs. &lt; 80%). The enrollment survey captured participant’s sociodemographic characteristics, including race and ethnicity, education, household income, and health literacy. We used a linear probability model to measure the interaction between the study arm and health literacy on AET adherence. Results: Among 304 women randomized (104 EUC, 98 App, and 102 App+Feedback), the 12-month follow-up retention rate was 88% (n = 266) and 19.4% reported low health literacy at enrollment. Low health literacy was more prevalent among Black (29.4%) vs. White (13.4%) participants (p &lt; 0.001), those with incomes below the federal poverty level (34.4% vs. 17.2% of those with higher incomes, p = 0.02), and those with only a high school degree or lower education (31.7%) vs. with those with some college or higher education (16.4%, p &lt; 0.01). In the low health literacy group, 80.0% of App+Feedback were AET adherent vs. 42.1% of EUC, a 37.9 percentage point (ppt) difference (95% CI: 4.1 to 71.7, p = 0.03); in higher literacy group adherence, 47.1% of App+Feedback vs. 59.0% of EUC were adherent, a -11.8 ppt difference (95% CI: -27.9 to 4.3, p = 0.15). Conclusions: A remote monitoring app with tailored educational text messages led to higher 1-year AET adherence among participants with low health literacy, but not for those with high health literacy. Clinical trial information: NCT03592771 .

The Fundamental Role of Linkage Uncertainty in Epidemiological Analysis of Big Data

BackgroundEpidemiologists increasingly work with linked “big data”. Uncertainty in record linkage may lead to biased inferences but is often overlooked. We evaluate the impact of linkage uncertainty on statistical inference in linked big data. MethodsWe developed a graphical framework for describing linkage uncertainty when linking multiple representations of the same entity, applied to de-identified data from South Africa’s national laboratory database. Through simulation, we systematically introduced linkage errors and measured their impact on overall accuracy (sensitivity, positive predictive value (PPV)). We evaluate how linkage errors affect bias and variance in point estimates for a hypothetical parameter of interest in clinical epidemiology: 24-month retention in care for HIV patients. We compare the roles of sampling error vs. linkage error as fundamental sources of uncertainty in datasets of varying sizes. ResultsWe simulated a population of 14,393 HIV patients, with a “true” 24-month retention of 38.7%. There were 338,056 true links. Introducing 4,200 false links reduced PPV by 5%. Removing 21,500 existing links decreased sensitivity by 5%. From 10 simulation runs, a 95% sensitivity led, on average, to a 7.4% overestimate in entries to care and a 2.2% (range: 2.1-2.4%) underestimate in 24-month retention. A 95% PPV resulted, on average, in a 7.5% underestimate in entries to care and a 1.8% (range: 1.5-2.0%) overestimate in 24-month retention. ConclusionWe observe that in a large sample, linkage uncertainty minimally impacts variance in point estimates but has a potentially large influence on the magnitude and direction, distinguishing it from typical sampling errors.

Improving Engagement in Residential Treatment for Substance Use Disorders: An Integrated Care Quality Improvement Project for Individuals With Mental Health and Substance Use Disorders

Substance use disorder continues to pose significant challenges in the United States, with increasing opioid-related fatalities. Residential recovery treatment programs are effective; however, high attrition rates impact successful long-term outcomes. This quality improvement project aimed to enhance patient engagement in treatment for mental health and substance use disorder to improve retention rates. It also implemented an integrated care approach incorporating psychotherapy, psychopharmacologic interventions, and recovery support services. The project was conducted using a 2-group predesign and postdesign, analyzing 134 admissions. The approach resulted in a statistically significant increase in patient engagement in treatment from 24% to 92%. Substance use relapse rates significantly reduced from 25% to 12%, and a clinically meaningful increase in the 3-month retention rate was noted. Integrated care is a promising strategy to improve outcomes for individuals receiving care for co-occurring disorders via residential treatment settings. Future studies should explore integrative models of care, patient motivation, and retention in residential treatment centers.

What Patient-related Factors Most Strongly Influence Autologous Fat Grafting Volume Retention in Breast Augmentation?

Background: Regarding autologous fat grafting for breast augmentation, the factors influencing volume retention are unclear. Few studies have assessed which factors, particularly patient-related variables, could affect volume retention and to what extent, without performing multivariate analysis. In this study, we performed three-dimensional breast volume measurements before and after autologous fat grafting, calculated the volume and volume retention, and investigated factors that may affect volume retention. Methods: A total of 204 breasts that underwent autologous fat grafting by the same surgeon at our hospital between May 25 and December 25, 2021 were included. Volumetric measurements were taken preoperatively and at 1, 3, and 6 months postoperatively using a three-dimensional camera; volume retention was calculated. Linear mixed model analysis was performed to examine the effects of age, body mass index, number of total autologous fat grafting procedures, pregnancy and lactation history, smoking status, fat processing techniques (sedimentation versus centrifugation), preoperative volume, and weight change at the 3- and 6-month postoperative volume retention analyses. Results: Using multivariate analysis, the preoperative volume was found to be a significant factor at 3 and 6 months. The preoperative volume affected fat volume retention rate by 0.004 (P = 0.001) and 0.008 (P = 0.011) per 10 mL at 3 and 6 months, respectively. Conclusions: The preoperative volume likely affected fat volume retention. Specifically, a 100-mL increase in the preoperative breast volume might increase the volume retention by 4%–8%. Preoperative volume is an important confounding factor for future studies.

Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care

BackgroundChallenges to engagement and retention on buprenorphine undermine treatment of individuals with opioid use disorder (OUD). Under the OUD Cascade of Care framework, we sought to identify patient characteristics and treatment response associated with superior clinical outcomes. MethodsA retrospective cohort study of specialty buprenorphine treatment patients entering treatment (n=19,487) based on EHR records from a large multi-state buprenorphine treatment network (2011–2019). Person-level care episodes were evaluated across treatment intake, engagement (i.e. 2+ visits in the month following intake), and retention at 6, 12, and 24 months. Time to achieving 90 days of continuous opioid abstinence was assessed using Cox proportional hazards regressions models and also assessed as a predictor of long-term retention. ResultsMost patients engaged (82.4 %), but retention steadily declined over 6-month (38.7 %), 12-month (26.2 %), and 24-month (17.1 %) timepoints. Opioid-positive baseline tests were associated with lower hazards of achieving continuous abstinence for both buprenorphine-positive (aHR=0.33, p<.001) and buprenorphine-negative (aHR=0.49,p<.001) intakes. Opioid abstinence was associated with buprenorphine-positive baseline testing (aHR=1.59,p<.001), especially for those testing opioid-negative (aHR=1.82,p<.001). Patients who achieved and sustained abstinence at 6 months in care were 4.1 and 5.5 times as likely to achieve 12-month and 24-month retention, respectively, compared to patients with intermittent opioid use. ConclusionTreatment discontinuation was concentrated early in care and buprenorphine and opioid status at intake were prognostic of achieving and sustaining abstinence. Early abstinence was associated with higher likelihood of subsequent stage progression. Implementing interventions to support early clinical stability for high-risk patients is critical to improve clinical outcomes.

Investigation of bone remodeling in gingival crevicular fluid in patients treated with rapid maxillary expansion during pubertal period

Purpose: We aimed to evaluate bone remodeling following 3-month and 6-month retention periods of rapid maxillary expansion (RME) in gingival crevicular fluid (GCF). Materials and Methods: 23 pubertal participants (15 girls- 8 boys, 12-15 years) with maxillary transversal deficiency were enrolled in the study. Following banded-type RME appliance was introduced into the mouth, RME protocol was initiated by turning the Hyrax screw twice daily (morning/evening) with ¼ activation. GCF samples were taken from right maxillary first molars at four different time points (T0: before the appliance was deployed, T1: following active phase, T2: at the end of the 3-month retention period, T3: at the end of the 6-month retention period) using paper strips. Probing depth, gingival index, plaque index, and bleeding percentage at probing were recorded. BALP, OPG, RANKL, and TNF-α levels were measured in GCF samples using ELISA kits. Results: Our study revealed that GCF's BALP and OPG levels remained unchanged over time in tension and pressure regions, and there were no statistically significant differences among regions at each time point (p&gt;0.05). RANKL level was statistically significantly increased in the buccal region (the pressure region) at time T1 (p=0.042). The palatinal region's TNF-α level was statistically significantly higher than the buccal region at T0, T2, and T3 time points (p=0.005, p=0.042, and p=0.006, respectively). Our study showed no correlation between 3-month and 6-month retention periods and biomarkers indicating RME's bone metabolic activities. Conclusions: Further studies with different retention periods and larger sample sizes are suggested.

Routine data in a primary care performance dashboard, Ethiopia.

To explore the feasibility of building a primary care performance dashboard using DHIS2 data from Ethiopia's largest urban (Addis Ababa), agrarian (Oromia) and pastoral (Somali) regions. We extracted 26 data elements reported by 12 062 health facilities to DHIS2 for the period 1July 2022 to 30June 2023. Focusing on indicators of effectiveness, safety and user experience, we built 14 indicators of primary care performance covering reproductive, maternal and child health, human immunodeficiency virus, tuberculosis, noncommunicable disease care and antibiotic prescription. We assessed data completeness by calculating the proportion of facilities reporting each month, and examined the presence of extreme outliers and assessed external validity. At the regional level, average completeness across all data elements was highest in Addis Ababa (82.9%), followed by Oromia (66.2%) and Somali (52.6%). Private clinics across regions had low completeness, ranging from 38.6% in Somali to 58.7% in Addis Ababa. We found only a few outliers (334 of 816 578 observations) and noted that external validity was high for 11 of 14 indicators of primary care performance. However, the 12-month antiretroviral treatment retention rate and proportions of patients with controlled diabetes or hypertension exhibited poor external validity. The Ethiopian DHIS2 contains information for measuring primary care performance, using simple analytical methods, at national and regional levels and by facility type. Despite remaining data quality issues, the health management information system is an important data source for generating health system performance assessment measures on a national scale.